Scientists try to trick tough cancers into responding to immunotherapy
NCT ID NCT03519412
Summary
This study tested a new two-step strategy for patients with advanced colorectal cancer that had stopped responding to standard treatments. First, some patients received a chemotherapy drug (temozolomide) with the goal of making their tumors more vulnerable. If that happened, they then received an immunotherapy drug (pembrolizumab). The main goal was to see if this sequence could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
Istituto Clinico Humanitas
Rozzano, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto Nazionale Tumori di Milano
Milan, Italy
Conditions
Explore the condition pages connected to this study.